MCID: FBR017
MIFTS: 60

Fibrosarcoma

Categories: Bone diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Fibrosarcoma

MalaCards integrated aliases for Fibrosarcoma:

Name: Fibrosarcoma 12 76 53 59 29 55 44 15 73
Neoplasms, Fibrous Tissue 44 73
Fibrosarcoma of Soft Tissue 12
Fibrous Tissue Neoplasm 12
Fibrocytic Tumor 12

Characteristics:

Orphanet epidemiological data:

59
fibrosarcoma
Prevalence: <1/1000000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:3355
SNOMED-CT 68 53654007
Orphanet 59 ORPHA2030
MESH via Orphanet 45 D005354
UMLS via Orphanet 74 C0016057
ICD10 via Orphanet 34 C49.9

Summaries for Fibrosarcoma

Disease Ontology : 12 A connective tissue cancer that has material basis in fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in a storiform pattern.

MalaCards based summary : Fibrosarcoma, also known as neoplasms, fibrous tissue, is related to breast adenocarcinoma and rheumatoid arthritis. An important gene associated with Fibrosarcoma is ETV6 (ETS Variant 6), and among its related pathways/superpathways are Integrin Pathway and Response to elevated platelet cytosolic Ca2+. The drugs Mechlorethamine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and breast, and related phenotypes are shRNA abundance <= 50% and growth/size/body region

Wikipedia : 76 Fibrosarcoma (fibroblastic sarcoma) is a malignant mesenchymal tumour derived from fibrous connective... more...

Related Diseases for Fibrosarcoma

Diseases in the Fibrosarcoma family:

Adult Fibrosarcoma Congenital Fibrosarcoma

Diseases related to Fibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
# Related Disease Score Top Affiliating Genes
1 breast adenocarcinoma 30.2 MMP2 MMP9 PLAU TNF
2 rheumatoid arthritis 30.0 JUN MALAT1 MMP1 MMP9 TIMP1 TNF
3 aortic aneurysm, familial thoracic 1 30.0 MMP1 MMP2 MMP9
4 pneumothorax 30.0 MMP1 MMP2 MMP9
5 cellular congenital mesoblastic nephroma 29.9 ETV6 NTRK3
6 aortic aneurysm, familial abdominal, 1 29.6 MMP1 MMP14 MMP2 MMP9 PLAU TIMP1
7 nasopharyngeal carcinoma 29.4 JUN MALAT1 MMP2 MMP9
8 breast cancer 29.1 JUN MALAT1 MMP1 MMP14 MMP2 MMP9
9 colorectal cancer 29.0 JUN MALAT1 MMP1 MMP14 MMP2 MMP9
10 small bowel fibrosarcoma 12.3
11 congenital fibrosarcoma 12.3
12 liver fibrosarcoma 12.3
13 heart fibrosarcoma 12.2
14 kidney fibrosarcoma 12.2
15 breast fibrosarcoma 12.2
16 fibrosarcoma of bone 12.2
17 adult fibrosarcoma 12.2
18 central nervous system fibrosarcoma 12.2
19 conventional fibrosarcoma 12.1
20 pediatric fibrosarcoma 12.1
21 dermatofibrosarcoma protuberans 11.6
22 infantile myofibromatosis 11.4
23 desmoid tumor 11.4
24 inflammatory myofibroblastic tumor 11.4
25 diaphyseal medullary stenosis with malignant fibrous histiocytoma 11.3
26 chromosome 17q11.2 deletion syndrome 11.1
27 extracranial arteriovenous malformation 10.3 MMP2 MMP9
28 adult mesoblastic nephroma 10.3 ETV6 NTRK3
29 focal myositis 10.3 MMP2 MMP9
30 villous adenocarcinoma 10.3 MMP2 MMP9
31 ischemic colitis 10.3 MMP2 MMP9 SERPINE1
32 amaurosis fugax 10.3 MMP9 SERPINE1
33 sarcoma 10.3
34 lentigo maligna melanoma 10.3 MMP2 MMP9
35 conjunctival nevus 10.3 MMP2 MMP9 TIMP1
36 spastic entropion 10.3 MMP1 MMP2 MMP9
37 internal hemorrhoid 10.3 MMP1 MMP2 MMP9
38 odontogenic myxoma 10.3 MMP1 MMP2 MMP9
39 maxillary cancer 10.3 MMP2 PLAU TIMP1
40 multicentric osteolysis, nodulosis, and arthropathy 10.3 MMP14 MMP2
41 hypertensive heart disease 10.3 MMP1 MMP2 MMP9
42 chronic actinic dermatitis 10.3 MMP1 MMP9
43 psammomatous meningioma 10.3 MMP2 MMP9
44 monoclonal gammopathy of uncertain significance 10.3 MAF MAFB TNF
45 winchester syndrome 10.3 MMP14 MMP2
46 transverse myelitis 10.3 MMP2 MMP9 TNF
47 autoimmune inner ear disease 10.3 MMP9 TIMP1 TNF
48 fungal keratitis 10.3 MMP9 TIMP1 TIMP2
49 inner ear disease 10.3 MMP9 TIMP1 TNF
50 acute transverse myelitis 10.3 MMP2 MMP9

Graphical network of the top 20 diseases related to Fibrosarcoma:



Diseases related to Fibrosarcoma

Symptoms & Phenotypes for Fibrosarcoma

GenomeRNAi Phenotypes related to Fibrosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.36 ETV6 JUN MAF MAFB MAFF MAFG

MGI Mouse Phenotypes related to Fibrosarcoma:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.4 ETV6 JAK1 JUN MAF MAFA MAFG
2 immune system MP:0005387 10.38 ETV6 JAK1 JUN MAF MAFB MAFG
3 cardiovascular system MP:0005385 10.37 ETV6 JAK1 JUN MAFB MMP14 MMP2
4 homeostasis/metabolism MP:0005376 10.37 ETV6 JAK1 JUN MAF MAFA MAFB
5 behavior/neurological MP:0005386 10.35 JAK1 JUN MAF MAFB MAFG MAFK
6 hematopoietic system MP:0005397 10.32 ETV6 JAK1 JUN MAFG MAFK MMP14
7 mortality/aging MP:0010768 10.31 ETV6 JAK1 JUN MAF MAFB MAFG
8 endocrine/exocrine gland MP:0005379 10.19 ETV6 JAK1 JUN MAFA MAFB MMP14
9 nervous system MP:0003631 10.15 JUN MAF MAFB MAFG MAFK MMP14
10 integument MP:0010771 10.11 ETV6 JAK1 JUN MAF MMP14 MMP9
11 craniofacial MP:0005382 10.09 JAK1 MAF MAFB MMP14 MMP2 PLAU
12 normal MP:0002873 10.02 ETV6 JAK1 JUN MAFA MAFB MAFF
13 neoplasm MP:0002006 10.01 ETV6 MMP1 MMP2 MMP9 PLAU SERPINE1
14 respiratory system MP:0005388 9.9 JAK1 JUN MAFB MMP14 MMP2 MMP9
15 renal/urinary system MP:0005367 9.8 JAK1 MAF MAFA MAFB MMP14 MMP9
16 skeleton MP:0005390 9.61 JAK1 JUN MAFB MMP14 MMP2 MMP9
17 vision/eye MP:0005391 9.23 JUN MAF MMP14 MMP2 MMP9 NTRK3

Drugs & Therapeutics for Fibrosarcoma

Drugs for Fibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
4
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
5
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
6
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
7
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 6055-19-2, 50-18-0 2907
9
Vincristine Approved, Investigational Phase 3,Phase 2 57-22-7, 2068-78-2 5978
10
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
11
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
12
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
13
Cyproheptadine Approved Phase 3 129-03-3 2913
14
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
15
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
16 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
17 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
18 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
19 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
21 Immunologic Factors Phase 3,Phase 2,Phase 1
22 Anti-Infective Agents Phase 3,Phase 2,Phase 1
23 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
24 Etoposide phosphate Phase 3,Phase 2
25 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
26 Antimitotic Agents Phase 3,Phase 1,Phase 2
27 Antirheumatic Agents Phase 3,Phase 2,Phase 1
28 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
29 Imatinib Mesylate Phase 2, Phase 3,Phase 1 220127-57-1 123596
30 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1
31 Serotonin Agents Phase 3
32 Anti-Allergic Agents Phase 3
33 Serotonin Antagonists Phase 3
34 Histamine H1 Antagonists Phase 3
35
Histamine Phosphate Phase 3 51-74-1 65513
36 Antipruritics Phase 3
37 Neurotransmitter Agents Phase 3
38 Dermatologic Agents Phase 3
39 Histamine Antagonists Phase 3
40 Gastrointestinal Agents Phase 3
41
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
42
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
43
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
44
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
45
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
46
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
47
Bevacizumab Approved, Investigational Phase 2 216974-75-3
48
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
49
Idarubicin Approved Phase 1, Phase 2 58957-92-9 42890
50
Nicotinamide Approved, Investigational Phase 1, Phase 2,Phase 2 98-92-0 936

Interventional clinical trials:

(show top 50) (show all 96)
# Name Status NCT ID Phase Drugs
1 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Unknown status NCT01344018 Phase 3
2 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
7 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
8 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
10 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
11 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
12 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Suspended NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
13 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
14 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
15 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
16 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
17 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
18 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Unknown status NCT01661283 Phase 2 everolimus;bevacizumab
19 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
20 Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) Completed NCT00542971 Phase 1, Phase 2 Idarubicin;Sorafenib;Ara-C
21 Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans Completed NCT00084630 Phase 2 imatinib mesylate
22 Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers Completed NCT00141765 Phase 2
23 BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer Completed NCT00326495 Phase 2 Cetuximab;BAY 43-9006
24 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
25 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
26 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2 imatinib mesylate
27 Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Completed NCT01962103 Phase 1, Phase 2 nab-paclitaxel;nab-paclitaxel
28 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
29 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
30 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
31 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
32 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
33 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
34 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
35 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
36 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
37 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
38 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
39 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
40 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
41 Combination Chemotherapy in Treating Patients With Advanced Cancer Completed NCT00004105 Phase 1, Phase 2 estramustine phosphate sodium;paclitaxel;vinorelbine ditartrate
42 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
43 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
44 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Completed NCT00002515 Phase 2 carboplatin;thiotepa;topotecan hydrochloride
45 Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans Completed NCT00243191 Phase 2 imatinib mesylate
46 Imatinib in Dermatofibrosarcoma Protuberans (DFSP) Completed NCT00122473 Phase 1, Phase 2 Imatinib (Glivec)
47 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Completed NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
48 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
49 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
50 Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib

Search NIH Clinical Center for Fibrosarcoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: fibrosarcoma

Genetic Tests for Fibrosarcoma

Genetic tests related to Fibrosarcoma:

# Genetic test Affiliating Genes
1 Fibrosarcoma 29

Anatomical Context for Fibrosarcoma

MalaCards organs/tissues related to Fibrosarcoma:

41
Bone, Lung, Breast, Endothelial, Kidney, Colon, Heart

Publications for Fibrosarcoma

Articles related to Fibrosarcoma:

(show top 50) (show all 1275)
# Title Authors Year
1
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. ( 29553955 )
2018
2
Genomics of a pediatric ovarian fibrosarcoma. Association with the DICER1 syndrome. ( 29459759 )
2018
3
Recurrent BCOR internal tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma. ( 29430000 )
2018
4
Solubilization of a Poorly Soluble B-Raf (Rapidly Accelerated Fibrosarcoma) Inhibitor: From Theory to Application. ( 28989016 )
2018
5
Oxygen microbubbles improve radiotherapy tumor control in a rat fibrosarcoma model - A preliminary study. ( 29630640 )
2018
6
Primary Renal Hybrid Low-grade Fibromyxoid Sarcoma-Sclerosing Epithelioid Fibrosarcoma: An Unusual Pediatric Case With EWSR1-CREB3L1 Fusion. ( 29426275 )
2018
7
CT and MRI Findings of Soft Tissue Adult Fibrosarcoma in Extremities. ( 29693010 )
2018
8
Caffeine induces metformin anticancer effect on fibrosarcoma in hamsters. ( 29762853 )
2018
9
Outcomes following surgical excision or surgical excision combined with adjunctive, hypofractionated radiotherapy in dogs with oral squamous cell carcinoma or fibrosarcoma. ( 29911943 )
2018
10
Juvenile Bronchopulmonary Fibrosarcoma. ( 29944599 )
2018
11
Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity. ( 29250984 )
2018
12
Spinal Sclerosing Epithelioid Fibrosarcoma at the Cervicothoracic Junction. ( 29574223 )
2018
13
Development of Orally Applicable, Combinatorial Drug-Loaded Nanoparticles for the Treatment of Fibrosarcoma. ( 29339136 )
2018
14
Disodium Cromolyn and Anti-podoplanin Antibodies Strongly Inhibit Growth of BHK 21/C13-derived Fibrosarcoma in a Chick Embryo Chorioallantoic Membrane Model. ( 29936460 )
2018
15
Successful management of congenital/infantile fibrosarcoma presenting as large, non-healing buttock ulceration. ( 29630153 )
2018
16
Primary tumor or metastasis? Extremely rare fibrosarcoma of the left atrial appendage. ( 29784427 )
2018
17
Sclerosing Epithelioid Fibrosarcoma of the Coccyx: A Case Report and Review of Literature. ( 29872588 )
2018
18
Rhodocetin-I+I^ selectively breaks the endothelial barrier of the tumor vasculature in HT1080 fibrosarcoma and A431 epidermoid carcinoma tumor models. ( 29854288 )
2018
19
Recurrent fibrosarcoma of maxillary sinus involving the cranial base: A rare case. ( 29970723 )
2018
20
Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. ( 29863809 )
2018
21
Peroxiredoxin 1 (PRDX1) Suppresses Progressions and Metastasis of Osteosarcoma and Fibrosarcoma of Bone. ( 29908016 )
2018
22
Fibrosarcoma arising in the paranasal sinus: a clinicopathological and radiological analysis. ( 29658783 )
2018
23
Unusual Presentation of Fibrosarcoma in a Child. ( 29615178 )
2018
24
ADAMTS-1 disrupts HGF/c-MET signaling and HGF-stimulated cellular processes in fibrosarcoma. ( 29355494 )
2018
25
Descending thoracic aortic aneurysm revealing metastasis of a soft tissue fibrosarcoma: a case report and review of the literature. ( 30473763 )
2018
26
Translocation Renal Cell Carcinoma in a Child Previously Treated for Infantile Fibrosarcoma. ( 28478739 )
2018
27
Mitochondria-targeted antioxidant SkQ1 suppresses fibrosarcoma and rhabdomyosarcoma tumour cell growth. ( 29995559 )
2018
28
CD11c+ MHCIIlo GM-CSF-bone marrow-derived dendritic cells act as antigen donor cells and as antigen presenting cells in neoepitope-elicited tumor immunity against a mouse fibrosarcoma. ( 30030558 )
2018
29
Lysophosphatidic acid receptor-2 (LPA2) and LPA5 regulate cellular functions during tumor progression in fibrosarcoma HT1080 cells. ( 30093116 )
2018
30
Expanding the spectrum of translocations in sclerosing epitheloid fibrosarcoma: A new case with EWSR1-CREB3L3 fusion. ( 30136738 )
2018
31
Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. ( 30187231 )
2018
32
Evaluation of anticancer effects of cerium oxide nanoparticles on mouse fibrosarcoma cell line. ( 30187476 )
2018
33
Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents. ( 30216849 )
2018
34
Canine oral fibrosarcoma: Changes in prognosis over the last 30 years? ( 30340654 )
2018
35
Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Sells. ( 30355481 )
2018
36
Tumor suppressive activity of PIWI-interacting RNA in human fibrosarcoma mediated through repression of RRM2. ( 30362638 )
2018
37
Immunomodulatory Effects of Blood Transfusion on Tumor Size, Metastasis, and Survival in Experimental Fibrosarcoma. ( 30369743 )
2018
38
Characterizing the DNA damage response in fibrosarcoma stem cells by in-situ cell tracking. ( 30373428 )
2018
39
Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells. ( 30404018 )
2018
40
Long Pentraxin 3-Mediated Fibroblast Growth Factor Trapping Impairs Fibrosarcoma Growth. ( 30443492 )
2018
41
The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. ( 30468696 )
2018
42
1-(5-Bromo-2-hydroxy-4-methoxyphenyl)ethanone [SE1] Inhibits MMP-9 Expression by Regulating NF-κB and MAPKs Signaling Pathways in HT1080 Human Fibrosarcoma Cells. ( 30519264 )
2018
43
Successful treatment of ETV6-NTRK3 fusion gene-negative infantile fibrosarcoma with metastatic lesion resistant to VAC chemotherapy. ( 30536487 )
2018
44
A rare case of intracardiac fibrosarcoma with myxoid features inducing venous occlusion in a dog - a case report. ( 30547774 )
2018
45
Antitumor effect of chondroitin AC lyase (PsPL8A) from Pedobacter saltans on melanoma and fibrosarcoma cell lines by in vitro analysis. ( 30550997 )
2018
46
The effects of gene therapy with granulocyte-macrophage colony-stimulating factor in the regression of tumor masses in fibrosarcoma mouse model. ( 28643761 )
2017
47
Fibrosarcoma of the eyelid in two sibling Czech wolfdogs. ( 28616389 )
2017
48
Harnessing the heart's resistance to malignant tumors: cardiac-derived extracellular vesicles decrease fibrosarcoma growth and leukemia-related mortality in rodents. ( 29245929 )
2017
49
Congenital infantile fibrosarcoma mimicking a cutaneous vascular lesion: a case report and review of the literature. ( 27910123 )
2017
50
Metastatic Sclerosing Epithelioid Fibrosarcoma in Bone Marrow. ( 28697683 )
2017

Variations for Fibrosarcoma

Cosmic variations for Fibrosarcoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM27895 GNAS bone,femur,osteosarcoma,fibroblastic c.602G>A p.R201H 20:58909366-58909366 4

Expression for Fibrosarcoma

Search GEO for disease gene expression data for Fibrosarcoma.

Pathways for Fibrosarcoma

Pathways related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.37 JAK1 JUN MMP1 MMP2 MMP9 PLAU
2
Show member pathways
13.28 JAK1 MAFF MAFG MAFK MMP1 PLAU
3 12.8 JAK1 JUN MMP1 MMP2 MMP9
4
Show member pathways
12.66 MMP1 MMP14 MMP2 MMP9 SERPINE1 TIMP1
5
Show member pathways
12.28 JAK1 JUN MMP1 MMP9 TNF
6 12.27 MMP2 MMP9 PLAU TNF
7
Show member pathways
12.24 JAK1 NTRK3 TIMP1 TIMP2 TNF
8 12.23 ETV6 MAF MMP9 PLAU
9
Show member pathways
12.21 JAK1 JUN MMP1 SERPINE1 TIMP1
10 12.13 JAK1 MMP1 MMP14 MMP2 MMP9 TNF
11 12.07 JUN MMP2 MMP9 TNF
12 12.01 MMP14 MMP2 MMP9 SERPINE1
13 11.94 JUN MMP14 MMP9 TNF
14 11.92 JUN MMP14 PLAU SERPINE1
15 11.87 JUN MMP2 SERPINE1 TNF
16 11.86 JAK1 MMP1 MMP2 MMP9 TIMP1 TNF
17 11.82 JUN MMP1 TNF
18 11.82 MMP2 MMP9 TIMP1 TIMP2
19
Show member pathways
11.79 JAK1 JUN TIMP1
20 11.75 JUN MMP2 MMP9
21
Show member pathways
11.73 JUN MAF TNF
22 11.71 MMP1 MMP2 MMP9
23
Show member pathways
11.7 MMP1 MMP14 MMP2 MMP9 TIMP1 TIMP2
24 11.65 JUN MMP2 MMP9
25 11.64 JUN MMP14 MMP2 MMP9
26
Show member pathways
11.6 JAK1 JUN MMP2 MMP9
27 11.6 MMP2 MMP9 PLAU TIMP1 TNF
28 11.57 JUN MMP2 PLAU
29 11.57 JAK1 JUN SERPINE1 TNF
30
Show member pathways
11.57 JUN MMP1 MMP2 MMP9 TNF
31 11.53 JAK1 JUN MMP1
32 11.53 JUN MMP2 TNF
33 11.51 JAK1 TIMP1 TNF
34 11.49 JUN MMP9 PLAU
35 11.48 MMP2 MMP9 PLAU TNF
36
Show member pathways
11.43 JUN MMP2 MMP9 PLAU
37 11.4 MMP1 MMP9 TIMP2
38 11.19 JUN MMP1 MMP2 MMP9 PLAU
39 11.16 MMP9 TIMP1 TIMP2
40 11.14 JUN MAF MAFA MAFB MAFF MAFG
41 11.01 MMP1 MMP14 MMP2 MMP9 PLAU SERPINE1
42 10.99 JUN NTRK3 TIMP1 TIMP2 TNF
43 10.99 JAK1 MMP1 TIMP1
44 10.93 MMP1 MMP9
45 10.8 PLAU SERPINE1

GO Terms for Fibrosarcoma

Cellular components related to Fibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 MMP14 MMP2 MMP9 PLAU SERPINE1 TIMP1
2 collagen-containing extracellular matrix GO:0062023 9.46 MMP2 MMP9 SERPINE1 TIMP2
3 extracellular matrix GO:0031012 9.1 MMP1 MMP14 MMP2 MMP9 TIMP1 TIMP2

Biological processes related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.87 JUN MMP14 MMP2 SERPINE1
2 positive regulation of cell migration GO:0030335 9.86 MMP14 MMP9 NTRK3 PLAU
3 cytokine-mediated signaling pathway GO:0019221 9.85 JAK1 MMP1 MMP2 MMP9 TIMP1 TNF
4 blood coagulation GO:0007596 9.81 MAFF MAFG MAFK PLAU
5 circadian rhythm GO:0007623 9.76 JUN NTRK3 SERPINE1
6 transcription by RNA polymerase II GO:0006366 9.76 ETV6 JUN MAF MAFA MAFB MAFF
7 ephrin receptor signaling pathway GO:0048013 9.75 MMP2 MMP9 NTRK3
8 response to cytokine GO:0034097 9.71 JUN TIMP1 TIMP2
9 response to organic substance GO:0010033 9.71 JUN TIMP1 TIMP2 TNF
10 response to hormone GO:0009725 9.7 MMP14 TIMP1 TIMP2
11 positive regulation of transcription by RNA polymerase II GO:0045944 9.65 ETV6 JUN MAF MAFA MAFB MAFF
12 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.62 JUN MMP2 MMP9 TNF
13 endodermal cell differentiation GO:0035987 9.61 MMP14 MMP2 MMP9
14 lens fiber cell differentiation GO:0070306 9.59 MAF NTRK3
15 collagen catabolic process GO:0030574 9.56 MMP1 MMP14 MMP2 MMP9
16 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.55 TIMP1 TIMP2
17 negative regulation of metallopeptidase activity GO:1905049 9.48 TIMP1 TIMP2
18 regulation of epidermal cell differentiation GO:0045604 9.46 MAFF MAFG
19 extracellular matrix disassembly GO:0022617 9.1 MMP1 MMP14 MMP2 MMP9 TIMP1 TIMP2
20 regulation of transcription, DNA-templated GO:0006355 10.1 ETV6 JUN MAF MAFA MAFB MAFF

Molecular functions related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.97 MMP1 MMP14 MMP2 MMP9 TIMP1 TIMP2
2 peptidase activity GO:0008233 9.92 MMP1 MMP14 MMP2 MMP9 PLAU
3 DNA-binding transcription factor activity GO:0003700 9.86 ETV6 JUN MAF MAFA MAFB MAFF
4 serine-type endopeptidase activity GO:0004252 9.77 MMP1 MMP14 MMP2 MMP9 PLAU
5 sequence-specific DNA binding GO:0043565 9.76 ETV6 JUN MAF MAFA MAFB MAFF
6 metallopeptidase activity GO:0008237 9.73 MMP1 MMP14 MMP2 MMP9
7 metalloendopeptidase activity GO:0004222 9.71 MMP1 MMP14 MMP2 MMP9
8 endopeptidase activity GO:0004175 9.69 MMP1 MMP14 MMP9
9 protease binding GO:0002020 9.62 SERPINE1 TIMP1 TIMP2 TNF
10 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.56 ETV6 JUN MAF MAFA MAFB MAFF
11 metalloendopeptidase inhibitor activity GO:0008191 9.54 TIMP1 TIMP2
12 proximal promoter DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001077 9.23 ETV6 JUN MAF MAFA MAFB MAFF
13 protein binding GO:0005515 10.41 ETV6 JAK1 JUN MAF MAFB MAFF
14 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 10.06 ETV6 JUN MAF MAFA MAFB MAFF

Sources for Fibrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....